Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 73

Results For "treatment"

3964 News Found

Altesa BioSciences unveils breakthrough data on Rhinovirus Drug at ICAR2026
R&D | March 23, 2026

Altesa BioSciences unveils breakthrough data on Rhinovirus Drug at ICAR2026

Vapendavir is an oral, potent, broad-spectrum antiviral active against rhinoviruses and related respiratory enteroviruses


TRIANA Biomedicines doses first patient in groundbreaking ALK+ lung cancer trial
News | March 23, 2026

TRIANA Biomedicines doses first patient in groundbreaking ALK+ lung cancer trial

The global, first-in-human, open-label trial will assess the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of TRI-611


Aesthetic Revolution: Global study reveals patients demand personalised, long-term beauty plans
News | March 21, 2026

Aesthetic Revolution: Global study reveals patients demand personalised, long-term beauty plans

The company, part of pharma powerhouse AbbVie, will showcase the findings—and the next evolution of its AA Signature framework—at AMWC 2026 in Monaco,


Dr. Reddy’s Laboratories launches India’s first DCGI-approved Semaglutide injection ‘Obeda’ for type 2 diabetes
News | March 21, 2026

Dr. Reddy’s Laboratories launches India’s first DCGI-approved Semaglutide injection ‘Obeda’ for type 2 diabetes

The announcement marks Dr. Reddy’s Day?1 entry into the GLP?1 receptor agonists therapy space and readiness to serve patients in India


Bristol Myers Squibb scores major win with new Opdivo nods for Hodgkin Lymphoma in US, EU
News | March 21, 2026

Bristol Myers Squibb scores major win with new Opdivo nods for Hodgkin Lymphoma in US, EU

These approvals represent a defining moment for people living with classical Hodgkin Lymphoma


Pfizer’s TALZENNA combo shows breakthrough results in aggressive prostate cancer
Clinical Trials | March 21, 2026

Pfizer’s TALZENNA combo shows breakthrough results in aggressive prostate cancer

The trial met its primary endpoint, with the combination therapy demonstrating a “statistically significant and clinically meaningful” improvement in radiographic progression-free survival


SK bioscience bags fresh backing to accelerate fight against respiratory disease
News | March 20, 2026

SK bioscience bags fresh backing to accelerate fight against respiratory disease

RSM01, a preventive treatment targeting respiratory syncytial virus (RSV), was licensed earlier this month from the Gates Medical Research Institute


Rhythm Pharmaceuticals’ Phase 3 EMANATE trial falls short of primary goals
Clinical Trials | March 20, 2026

Rhythm Pharmaceuticals’ Phase 3 EMANATE trial falls short of primary goals

The study included four independent genetic substudies targeting obesity caused by heterozygous variants in the POMC/PCSK1, LEPR, SRC1 (NCOA1), and SH2B1 genes